Investment Rating - The industry rating is maintained at "Overweight" [5][10] Core Insights - The vaccine industry is experiencing a transition from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term outlook remains positive driven by policy, demand, and technology [9][10][30] - Domestic companies like Zhifei Biological and Wantai Biological are making progress in multi-valent vaccines and genetically engineered recombinant vaccines, indicating differentiated technological paths and process upgrades [3] - GSK's hepatitis B vaccine is re-entering the Chinese market through a strategic partnership, highlighting multinational companies' flexible approaches to strengthen their vaccine business in China [3] Summary by Sections Domestic and International Vaccine Dynamics - Zhifei Biological's acellular pertussis-diphtheria-tetanus combined vaccine has entered Phase I clinical trials [3] - Wantai Biological's trivalent rotavirus subunit vaccine has received clinical trial approval [3] - GSK announced a strategic cooperation to reintroduce its hepatitis B vaccine in China [3] Market Performance - The vaccine sector saw a decline of 4.93% last week, with a cumulative drop of 18.64% since 2025 [4][12] - The overall pharmaceutical sector showed mixed performance, with the pharmaceutical index rising by 1.56% [4] Company Performance - Companies like Jindike, Olin Biological, and Wantai Biological performed well, while companies like CanSino and Liaoning Chengda lagged behind [5] Valuation - The vaccine sector's PE (ttm) was 65.37X, down 1.47X week-on-week, with a PB (lf) of 1.21X, also showing a slight decrease [8] Investment Recommendations - The vaccine industry is under pressure, with a focus on innovation and international expansion as key strategies for long-term growth [9][10][30] - Companies with strong R&D capabilities and differentiated product offerings are recommended for investment, particularly focusing on those with high technical barriers [10][30]

证券代码：300122 证券简称：智飞生物 公告编号：2025-04 重庆智飞生物制品股份有限公司 关于吸附无细胞百白破（组分）b 型流感嗜血杆菌（结合） 联合疫苗临床试验申请获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 1 二、获得受理的意义 截至目前，经查询国家药品监督管理局网站，国内有 1 款无细胞百白破 b 型 流感嗜血杆菌联合疫苗上市销售，采用共纯化技术制备。智飞绿竹研制的组分百 白破-Hib 四联疫苗相比共纯化工艺，百日咳升级了百日咳抗原纯化及配制工艺， 系采用三个单独纯化的百日咳有效抗原组分联合白喉、破伤风、Hib 有效组分配 制的质量均一的疫苗产品，可替代免疫规划疫苗中的百白破疫苗。目前，国内暂 无组分百白破-Hib 四联疫苗获批上市，市场前景广阔。 组分百白破-Hib 四联疫苗是公司聚焦创新技术、增强科研攻关的成果。若本 项目进展顺利，将与公司处于Ⅲ期临床试验的组分百白破疫苗形成协同效应，进 一步夯实公司多联疫苗矩阵布局，强化公司的市场竞争优势，为实现长远目标奠 定坚实基础。 三、风险提示 1、药品研制是非常复杂严谨的科学活 ...